TETmedical Names Arjun Ishwar Chief Commercial Officer to Lead Commercial Strategy and Accelerate NSE-FAST® Toward Market Launch and Rapid GrowthVeteran MedTech Commercial Builder Who Has Scaled Businesses from First Dollar to $100M+ in Revenue, Secured Coverage and Reimbursement Pathways, and Led International Expansion Joins TETmedical Ahead of Its Pivotal Study and Planned Commercial Launch
TETmedical Strengthens Board of Directors with Appointment of Marc Lebel and Patrick McBrayer, Veteran Life Sciences Entrepreneurs and Company BuildersNew Directors Bring Track Record of Founding, Scaling, and Exiting Institutionally-Backed MedTech and Life Sciences Companies as TETmedical Advances Its Pivotal Study
TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic StrokeFAIR HAVEN, N.J. and ITHACA, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- TETmedical, Inc., a clinical stage medical diagnostics company developing rapid tools for diagnosing acute neurological injury based on its patented Tethered Enzyme Technology (TET), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NSE-FAST® (Neuron Specific Enolase — Functional Activity Stroke Test), a rapid in vitro diagnostic assay intended to aid in the diagnosis of acute ischemic stroke.
